Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

NCT04439006 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Aplastic Anemia
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Monoclonal B-Cell Lymphocytosis
Monoclonal Gammopathy of Undetermined Significance
Myelodysplastic Syndrome
Symptomatic COVID-19 Infection Laboratory-Confirmed

Interventions

OTHER: Best Practice
DRUG: Ibrutinib

Sponsor

Jennifer Woyach

Collaborators

[object Object]